F2-isoprostanes as biomarkers of late onset alzheimer’s disease

Thomas J. Montine, Joseph Quinn, Jeffrey Kaye, Jason D. Morrow

Research output: Chapter in Book/Report/Conference proceedingChapter

Abstract

What is commonly referred to as Alzheimer's disease (AD) is really a syndrome, a common clinicopathologic entity that has multiple causes. Unusual forms of this syndrome are caused by highly penetrant autosomal-dominant mutations in one of three different genes: amyloid precursor protein (APP) gene, presenilin (PS) 1 gene, or PS 2 gene.1 Apparently, the same pathologic processes very commonly afflict adults with trisomy 21 or Down's syndrome. However, it is late onset AD (LOAD) that represents a significant and growing public health burden, a “silent epidemic,” currently affecting between 2.5 and 4 million people in the United States, and more than 10 million people worldwide.2,3 The causes of LOAD are not yet clarified, but several environmental and genetic risk factors have been identified, the most potent of these being inheritance of the e4 allele of the apolipoprotein (apo) E gene.4 It is estimated that LOAD will grow to staggering prevalence in the next generation with an estimated 8 to 12 million patients by the year 2050 in the United States alone. In addition to the untold suffering it causes patients and their families, AD is the third most costly medical condition in the United States.5-7 As the number of patients afflicted continues to mount, the need for safe and effective therapy to delay or avert LOAD will become imperative.8.

Original languageEnglish (US)
Title of host publicationOxidative Stress and Age-Related Neurodegeneration
PublisherCRC Press
Pages147-158
Number of pages12
ISBN (Electronic)9781420026559
ISBN (Print)9780849337253
StatePublished - Jan 1 2005

Fingerprint

F2-Isoprostanes
Biomarkers
Alzheimer Disease
Genes
Down Syndrome
Presenilin-2
Presenilin-1
Amyloid beta-Protein Precursor
Apolipoproteins E
Public health
Pathologic Processes
Psychological Stress
Public Health
Alleles
Mutation
Therapeutics

ASJC Scopus subject areas

  • Neuroscience(all)
  • Biochemistry, Genetics and Molecular Biology(all)
  • Medicine(all)

Cite this

Montine, T. J., Quinn, J., Kaye, J., & Morrow, J. D. (2005). F2-isoprostanes as biomarkers of late onset alzheimer’s disease. In Oxidative Stress and Age-Related Neurodegeneration (pp. 147-158). CRC Press.

F2-isoprostanes as biomarkers of late onset alzheimer’s disease. / Montine, Thomas J.; Quinn, Joseph; Kaye, Jeffrey; Morrow, Jason D.

Oxidative Stress and Age-Related Neurodegeneration. CRC Press, 2005. p. 147-158.

Research output: Chapter in Book/Report/Conference proceedingChapter

Montine, TJ, Quinn, J, Kaye, J & Morrow, JD 2005, F2-isoprostanes as biomarkers of late onset alzheimer’s disease. in Oxidative Stress and Age-Related Neurodegeneration. CRC Press, pp. 147-158.
Montine TJ, Quinn J, Kaye J, Morrow JD. F2-isoprostanes as biomarkers of late onset alzheimer’s disease. In Oxidative Stress and Age-Related Neurodegeneration. CRC Press. 2005. p. 147-158
Montine, Thomas J. ; Quinn, Joseph ; Kaye, Jeffrey ; Morrow, Jason D. / F2-isoprostanes as biomarkers of late onset alzheimer’s disease. Oxidative Stress and Age-Related Neurodegeneration. CRC Press, 2005. pp. 147-158
@inbook{4e0fcf14352b4952a97f81a15361eed6,
title = "F2-isoprostanes as biomarkers of late onset alzheimer’s disease",
abstract = "What is commonly referred to as Alzheimer's disease (AD) is really a syndrome, a common clinicopathologic entity that has multiple causes. Unusual forms of this syndrome are caused by highly penetrant autosomal-dominant mutations in one of three different genes: amyloid precursor protein (APP) gene, presenilin (PS) 1 gene, or PS 2 gene.1 Apparently, the same pathologic processes very commonly afflict adults with trisomy 21 or Down's syndrome. However, it is late onset AD (LOAD) that represents a significant and growing public health burden, a “silent epidemic,” currently affecting between 2.5 and 4 million people in the United States, and more than 10 million people worldwide.2,3 The causes of LOAD are not yet clarified, but several environmental and genetic risk factors have been identified, the most potent of these being inheritance of the e4 allele of the apolipoprotein (apo) E gene.4 It is estimated that LOAD will grow to staggering prevalence in the next generation with an estimated 8 to 12 million patients by the year 2050 in the United States alone. In addition to the untold suffering it causes patients and their families, AD is the third most costly medical condition in the United States.5-7 As the number of patients afflicted continues to mount, the need for safe and effective therapy to delay or avert LOAD will become imperative.8.",
author = "Montine, {Thomas J.} and Joseph Quinn and Jeffrey Kaye and Morrow, {Jason D.}",
year = "2005",
month = "1",
day = "1",
language = "English (US)",
isbn = "9780849337253",
pages = "147--158",
booktitle = "Oxidative Stress and Age-Related Neurodegeneration",
publisher = "CRC Press",

}

TY - CHAP

T1 - F2-isoprostanes as biomarkers of late onset alzheimer’s disease

AU - Montine, Thomas J.

AU - Quinn, Joseph

AU - Kaye, Jeffrey

AU - Morrow, Jason D.

PY - 2005/1/1

Y1 - 2005/1/1

N2 - What is commonly referred to as Alzheimer's disease (AD) is really a syndrome, a common clinicopathologic entity that has multiple causes. Unusual forms of this syndrome are caused by highly penetrant autosomal-dominant mutations in one of three different genes: amyloid precursor protein (APP) gene, presenilin (PS) 1 gene, or PS 2 gene.1 Apparently, the same pathologic processes very commonly afflict adults with trisomy 21 or Down's syndrome. However, it is late onset AD (LOAD) that represents a significant and growing public health burden, a “silent epidemic,” currently affecting between 2.5 and 4 million people in the United States, and more than 10 million people worldwide.2,3 The causes of LOAD are not yet clarified, but several environmental and genetic risk factors have been identified, the most potent of these being inheritance of the e4 allele of the apolipoprotein (apo) E gene.4 It is estimated that LOAD will grow to staggering prevalence in the next generation with an estimated 8 to 12 million patients by the year 2050 in the United States alone. In addition to the untold suffering it causes patients and their families, AD is the third most costly medical condition in the United States.5-7 As the number of patients afflicted continues to mount, the need for safe and effective therapy to delay or avert LOAD will become imperative.8.

AB - What is commonly referred to as Alzheimer's disease (AD) is really a syndrome, a common clinicopathologic entity that has multiple causes. Unusual forms of this syndrome are caused by highly penetrant autosomal-dominant mutations in one of three different genes: amyloid precursor protein (APP) gene, presenilin (PS) 1 gene, or PS 2 gene.1 Apparently, the same pathologic processes very commonly afflict adults with trisomy 21 or Down's syndrome. However, it is late onset AD (LOAD) that represents a significant and growing public health burden, a “silent epidemic,” currently affecting between 2.5 and 4 million people in the United States, and more than 10 million people worldwide.2,3 The causes of LOAD are not yet clarified, but several environmental and genetic risk factors have been identified, the most potent of these being inheritance of the e4 allele of the apolipoprotein (apo) E gene.4 It is estimated that LOAD will grow to staggering prevalence in the next generation with an estimated 8 to 12 million patients by the year 2050 in the United States alone. In addition to the untold suffering it causes patients and their families, AD is the third most costly medical condition in the United States.5-7 As the number of patients afflicted continues to mount, the need for safe and effective therapy to delay or avert LOAD will become imperative.8.

UR - http://www.scopus.com/inward/record.url?scp=85057944574&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85057944574&partnerID=8YFLogxK

M3 - Chapter

SN - 9780849337253

SP - 147

EP - 158

BT - Oxidative Stress and Age-Related Neurodegeneration

PB - CRC Press

ER -